Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials

Journal of Medicinal Chemistry - United States
doi 10.1021/acs.jmedchem.5b01882
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Chemical Society (ACS)

Related search

Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-Terminal Domain (BET) Proteins

English

Suppression of Interferon Β Gene Transcription by Inhibitors of Bromodomain and Extra-Terminal (BET) Family Members

Biochemical Journal
BiochemistryCell BiologyMolecular Biology
2015English

Inhibition of Bromodomain and Extra-Terminal Proteins (BET) as a Potential Therapeutic Approach in Haematological Malignancies: Emerging Preclinical and Clinical Evidence

Therapeutic Advances in Hematology
Hematology
2015English

Preclinical Evaluation of the BET Bromodomain Inhibitor BAY 1238097 for the Treatment of Lymphoma

British Journal of Haematology
Hematology
2017English

The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma

Molecular Cancer Therapeutics
Cancer ResearchOncology
2016English

Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate

English

Bromodomain and Extra-Terminal Protein Inhibition Attenuates Neutrophil-Dominant Allergic Airway Disease

Scientific Reports
Multidisciplinary
2017English

Identification of Haptoglobin as a Natural Inhibitor of Trypanocidal Activity in Human Serum.

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1995English

BET Protein Bromodomain Inhibitor-Based Combinations Are Highly Active Against Post-Myeloproliferative Neoplasm Secondary AML Cells

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy